Molecular basis of variability in EGFR-targeted therapy response in non-small cell lung cancer.

Lung cancer is the most fatal malignant tumor worldwide, with non-small cell lung cancer (NSCLC) being the predominant pathological subtype. The development of NSCLC is driven by mutations in the epidermal growth factor receptor (EGFR), and EGFR tyrosine kinase inhibitors (EGFR-TKIs) are employed as targeted therapies for first-line treatment of advanced NSCLC patients harboring EGFR mutations. However, variations in molecular structures, concurrent mutations, and mechanisms of therapeutic resistance contribute to prognostic disparities among different EGFR subgroups. This review primarily summarizes the molecular structural basis and differential treatment responses associated with distinct types of EGFR mutations in NSCLC. [ABSTRACT FROM AUTHOR]